Clinical Trials Logo

Primary Immune Thrombocytopenia clinical trials

View clinical trials related to Primary Immune Thrombocytopenia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06071520 Completed - Clinical trials for Primary Immune Thrombocytopenia

Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study

Start date: March 1, 2023
Phase:
Study type: Observational

Description of the use of fostamatinib in patients with PTI in the Andalusian region.

NCT ID: NCT05621330 Completed - Clinical trials for Primary Immune Thrombocytopenia

Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Start date: October 18, 2019
Phase: Phase 3
Study type: Interventional

QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with primary chronic ITP.

NCT ID: NCT05551624 Completed - Clinical trials for Primary Immune Thrombocytopenia

Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine

Start date: July 4, 2018
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to assess the ability of Atorvastatin and N-acetyl cysteine to elevate the blood (serum) platelet count in patients with Immune Thrombocytopenia as a mean of a new treatment.

NCT ID: NCT04687072 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

ADVANCE SC
Start date: December 11, 2020
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod PH20 SC treatment in adult patients with primary ITP.

NCT ID: NCT04188379 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

ADVANCE
Start date: December 16, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.

NCT ID: NCT03102593 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Start date: March 13, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia.

NCT ID: NCT01727232 Completed - Clinical trials for Primary Immune Thrombocytopenia

Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

Start date: January 2007
Phase: N/A
Study type: Observational

The aim of this large French multicentric retrospective study was to compare the efficacy and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .